YILI(SH:600887) Nei Meng Gu Ri Bao·2026-02-12 10:42Core Insights - The National Health Commission of China announced that the probiotic strain YLGB-1496, developed by the National Dairy Technology Innovation Center in collaboration with Yili, has been included in the list of probiotics suitable for infant food, marking the first domestically developed strain for this purpose in China [1][3] Group 1: Industry Impact - The approval of YLGB-1496 represents a significant breakthrough for the domestic probiotic industry in China, reducing reliance on imported probiotics for infants [3] - YLGB-1496 is designed to efficiently utilize human milk oligosaccharides (HMO), which are crucial for the gut microbiota of breastfed infants, thus helping to establish a healthy early gut microecological system [3] Group 2: Research and Development - A series of rigorous clinical studies on infants have been conducted by Yili in collaboration with the National Dairy Technology Innovation Center and other authoritative institutions, leading to the granting of 15 Chinese invention patents related to this strain and its technology [3][4] Group 3: Commercialization - Jinqi Biotechnology, a platform under Yili with a national-level probiotic industrialization production demonstration line, is responsible for the industrialization and commercialization of YLGB-1496, supporting the upgrade of the health food industry towards high quality and diversification [4] - The strain has already been successfully applied in various products, including QQ Star's "Jianhu Mama," Jinhu Cheese Sticks, and Meiyitian Mixed Fruit and Vegetable Juice, with plans for broader application in infant formula and other core product lines [4]